Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses

Patent metadata

Field	Value
Publication number	US-11021475-B2
Application number	US-201916687279-A
Country	US
Kind code	B2
Filing date	Nov 18, 2019
Priority date	Nov 8, 2012
Publication date	Jun 1, 2021
Grant date	Jun 1, 2021

Abstract

Compounds having the following formula I:

or a stereoisomer or pharmaceutically-acceptable salt thereof, where R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

First claim

What is claimed is:

1. A method of treating psoriasis in a subject, the method comprising orally administering to the subject a composition comprising a compound of the following formula:

which is 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide.

2. The method according to claim 1 , wherein the composition is in the form of a tablet, a capsule, granules, a powder, or a liquid formulation.

3. The method according to claim 2 , wherein the composition is in the form of a tablet.

4. The method according to claim 2 , wherein the composition is in the form of a capsule.

5. The method according to claim 2 , wherein the composition is in the form of granules.

6. The method according to claim 2 , wherein the composition is in the form of a powder.

7. The method according to claim 2 , wherein the composition is in the form of a liquid formulation.

8. The method according to claim 7 , wherein the composition is in the form of a syrup.

9. The method according to claim 1 , wherein the composition is orally administered to the subject 1 to 4 times per day.

10. The method according to claim 9 , wherein the composition is in the form of a tablet.

11. A method of treating psoriasis in a subject, the method comprising orally administering to the subject, 1 to 2 times per day, a tablet comprising a compound of the following formula:

which is 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide.

12. The method according to claim 11 , wherein 1 tablet per day is administered to the subject.

13. The method according to claim 11 , wherein 2 tablets per day are administered to the subject.

14. A method of treating psoriasis in a subject, the method comprising orally administering to the subject, 1 to 2 times per day, a tablet comprising a pharmaceutically acceptable salt of a compound of the following formula:

which is 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide.

15. The method according to claim 14 , wherein 1 tablet per day is administered to the subject.

16. The method according to claim 14 , wherein 2 tablets per day are administered to the subject.

Assignees

• Bristol Myers Squibb Co

Inventors

• Moslin Ryan M
• Weinstein David S
• Wrobleski Stephen T

Classifications

• C07D401/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D401/14

  containing three or more hetero rings · CPC title

• C07D403/12

  linked by a chain containing hetero atoms as chain links · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• A61P17/06

  Antipsoriatics · CPC title